Reata Pharmaceuticals Down 30% After Hours on FDA Advisory Panel Vote

By Josh Beckerman

Reata Pharmaceuticals Inc. shares were recently down 30% to $38 after hours after the company received a negative opinion from a Food and Drug Administration advisory committee for its new drug application for bardoxolone methyl.

Reata shares were halted all day Wednesday.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

12-08-21 1910ET